DCM
DNLI icon

Defilade Capital Management’s Denali Therapeutics DNLI Stock Holding History

Defilade Capital Management’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.1M Sell
391,866
-968,103
-71% -$19.9M 1.35% 32
2026
Q1 		$26.1M Buy
1,359,969
+703,256
+107% +$14M 3.67% 12
2025
Q4 		$10.8M Buy
+656,713
New +$11.1M 1.47% 24

Other funds holding DNLI

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Defilade Capital Management's DNLI Position: Q2 2026 in Review

Defilade Capital Management reduced its Denali Therapeutics (DNLI) stake by 71% in Q2 2026, selling an estimated $19.9M and leaving 391,866 shares worth $10.1M. The position accounts for 1.35% of the portfolio, ranked #32.

Defilade Capital Management first reported a position in DNLI in Q4 2025 and has held it in 3 quarters since. The position peaked at $26.1M in Q1 2026. 292 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

  • Defilade Capital Management held 391,866 shares of Denali Therapeutics worth $10.1M as of Q2 2026.
  • Defilade Capital Management sold 968,103 Denali Therapeutics shares in Q2 2026, an estimated $19.9M.
  • Denali Therapeutics made up 1.35% of Defilade Capital Management's portfolio in Q2 2026, its #32 holding.
  • Defilade Capital Management first reported a position in Denali Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Defilade Capital Management's Denali Therapeutics position peaked at $26.1M in Q1 2026.
  • 292 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on Defilade Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.